Icon acquires Mapi Group, ups financial guidances

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Kritchanut)
(Image: iStock/Kritchanut)
Icon plc is expanding its commercialization offerings through its has acquisition of Mapi Group, a global research company.

The Mapi Group was founded in 1974 and provides real-world evidence, strategic regulatory services, pharmacovigilance, market access, and language services to support commercialization.

Through the acquisition, Icon will also have access to Mapi Research Trust, a non-profit that provides outcomes research globally.

Per the company’s website, the Trust features more than 4,000 clinical outcomes assessments (COA), more than 40,000 COA translations, and a research library with more than 29,000 COAs.

Dr. Steve Cutler, Icon CEO commented in the press release: “Our customers will also benefit from ICON’s access to the industry’s broadest set of COA tools and instruments as well as new and enhanced real world data set​s.”

Following the acquisition, Icon has increased its earnings and revenue guidances.

According to the company’s earnings results, also published today, the earnings guidance has been increased from a range of $5.06 - $5.26bn to $5.18 - $5.38bn. Revenue guidance increased from a range of $1.70 - $1.75bn to $1.74 - $1.77bn.

Icon reported gross business wins of $649m in the second quarter and cancelations of $86m, which resulted in net business wins of $563 million and a net book to bill of 1.31.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

Related suppliers

Follow us

Products

View more

Webinars